Clinical trial

REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)

Recruiting now · Not applicable · 1 countries · Registry ID NCT07412782

Recruiting nowNot applicableInterventional

What this study is about

This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free ultrasound technology. Bone health is crucial during childhood, when peak bone mass develops, and reduced BMD is associated with increased fracture risk. DXA is the current reference method but has limitations in children, including radiation exposure and growth-related measurement issues. REMS has been validated in adults and shows promise in pediatrics, despite the lack of reference values. The study is a single-center, national, non-profit interventional study lasting about 12 months. Participants will undergo REMS BMD measurement, clinical history collection, and assessment of anthropometric and pubertal parameters, with prior DXA data collected when available. The primary aim is to describe BMD values measured by REMS in pediatric osteoporosis, with secondary aims including subgroup analyses and comparison with DXA. A sample of 100 patients is planned. Statistical analyses will assess BMD distributions, correlations with clinical variables, and agreement between REMS and DXA using correlation coefficients and Bland-Altman analysis.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age5 Years to 18 Years

SexAll

Healthy volunteersNot accepted

ConditionOsteogenesis Imperfecta, Osteoporosis, Hypogonadisms, Neoplasia, Obesity & Overweight, Malnutrition (Calorie), Hypercortisolism, Growth Hormone Deficiency (GHD), Osteopenia

Full registry criteria

Inclusion Criteria: * Written informed consent from adult patients or parents/legal guardians * Age between 5 and 18 years * Both sexes and all ethnicities * Known condition negatively affecting bone health Exclusion Criteria: \- Age below 5 years or over 18 years

Treatments and study arms

REMS

Diagnostic Test

REMS (Radiofrequency Echographic Multi Spectrometry) technology, a non-invasive, radiation-free ultrasound system to detect BMD. REMS has obtained FDA and CE approval and has been validated

Primary outcomes

BMD values in primary osteoporosisAt the enrollement

Mean and median of Bone Mineral Density values obtained in the pediatric population affected by primary osteoporosis

Study locations

1 locations were listed when this page was built. The first 40 are shown.

AOU IRCCS Meyer🇮🇹 Florence, Tuscany, Italy

Open map